SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9, 1998
SYNAPTIC PHARMACEUTICAL CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
0-27324 22-285-9704
(Commission File Number) (I.R.S. Employer Identification No.)
215 College Road
Paramus, New Jersey 07652-1431
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (201) 261-1331
Page 1 of 3 Pages
<PAGE>
Item 5. Other Events
The Company, in collaboration with Eli Lilly and Company ("Lilly"), is
currently conducting drug discovery programs focused on a number of serotonin
receptor subtypes and therapeutic applications. The current status of certain of
these programs is summarized in the following table:
Program(1) Receptor(s) Primary Indication(s) Status(2)
- -------------------------------------------------------------------------------
Serotonin 1F Acute Migraine Phase II Clinical
2B Migraine Prophylaxis Late Preclinical
__(3) Depression Late Preclinical
1A Smoking Cessation Early Preclinical
2C Obesity Early Preclinical
(1) The Company is working with Lilly on receptor and drug discovery
programs in addition to those programs referenced in the above table.
In general, the drug discovery and receptor discovery programs that are
specifically referenced in the above table are at more advanced stages
of development than those that are not specifically referenced in the
table.
(2) "Early Preclinical" refers to the stage at which one or more leads have
been identified and are being tested in in vitro or in vivo model
systems for one or more indications. In addition, at this stage, lead
compounds may have been shown to be active in animal models for one or
more indications and preliminary toxicology and pharmacokinetics
studies will also have been concluded.
"Late Preclinical" refers to the stage at which a clinical candidate
has been selected, scale-up of such candidate is underway or completed,
and toxicology and pharmacokinetics studies are planned or underway.
"Phase II Clinical" refers to the stage at which a drug candidate is
administered to a small sample of the actual intended patient
population to seek to assess the efficacy of the drug candidate for the
specific targeted indication, to determine dose tolerance and the
optimal dose range and to gather additional information relating to
safety and potential adverse effects.
(3) This information is confidential to the Company and Lilly.
Page 2 of 3 Pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: January 9, 1998
SYNAPTIC PHARMACEUTICAL CORPORATION
(Registrant)
By:/s/ Kathleen P. Mullinix
----------------------------------
Name: Kathleen P. Mullinix
Title: President and Chief Executive Officer
Page 3 of 3 Pages
<PAGE>
